Envirotainer completes integration of va-Q-tec’s pharma business, advancing the future of pharma cold chain

Newly combined capabilities set a higher standard for temperature-controlled logistics  

Stockholm, September 4, 2024: Envirotainer, the specialist in temperature-sensitive pharmaceutical shipments, is embarking on the next phase of its journey to set a new standard for the future of pharmaceutical cold chain logistics with the completion of its strategic integration with va-Q-tec.

As the pharmaceutical industry faces growing demands for more reliable and flexible cold chain solutions, Envirotainer has strengthened its portfolio with the addition of advanced passive cooling technologies to help lead this transformation.

With Envirotainer’s extended range of solutions, pharmaceutical companies can now transport products at any temperature, size and at any stage of the product lifecycle, whether for clinical trials, active pharmaceutical ingredients (APIs), or finished medicines. This comprehensive capability spans the entire range of pharmaceuticals, from precision medicines and advanced cell and gene therapies, to commercial distribution of vaccines and chronic disease treatments.

Using the combined R&D expertise of both companies, Envirotainer will bring new, innovative cold chain solutions to the market in 2025. These upcoming developments will provide pharmaceutical companies with even more reliable and efficient options for safely transporting sensitive medicines, further enhancing reliability and efficiency.

Envirotainer’s expanded capabilities now enable pharmaceutical companies to transport their products to even the most challenging regions. Supported by an expanded global network, the company’s solutions are designed to keep medicines safe under the most extreme conditions, offering peace of mind to those responsible for their distribution.

The integration opens up new possibilities for pharmaceutical companies to optimise their cold chain logistics. With a broader range of solutions available, customers can now choose the best options for their specific needs—whether that means finding the most cost-effective approach, providing flexibility in distribution, or adapting quickly to changing conditions. As the industry advances, these options also support a growing commitment to environmental sustainability.

This new chapter in cold chain logistics also brings advanced digital services and enhanced customer support to a broader range of pharmaceutical companies. These services include real-time monitoring, predictive analytics and 24/7 customer assistance, helping pharmaceutical companies maintain strict temperature control and compliance throughout the shipping process. This level of precision and support helps to minimise the risk of temperature deviations, a critical factor in the successful distribution of sensitive medicines.

David Simonsson, CEO at Envirotainer said, “This integration marks a significant step forward for our customers and company. By combining the best of active and passive technologies, we’re better equipped to meet the evolving needs of the pharmaceutical industry, helping vital medicines reach patients safely, no matter where they are. As we continue to innovate, sustainability remains central to our mission, and we’ll continue to offer solutions that not only protect the efficacy of medicines but also align with environmental best practices. This is the beginning of a new era for us, one where we can make an even greater impact on global health.”

About Envirotainer 

Envirotainer transports life-saving pharmaceuticals around the world with innovative temperature-controlled solutions.

With 40 years leading the industry, the world's largest pharmaceutical companies trust us to deliver. We offer the widest choice of cold chain solutions with a range of shipment monitoring services, all backed by our extensive global network to get your product to where it needs to be, precisely when it needs to be there.

When it comes to sustainability, we lead by example. Our ambitious science-based targets guide us, so we can reduce not only our emissions but our customers', too. Our transparent reporting, data-driven approach, and precise CO2 calculations allow us to measure our environmental impact all the way down to emissions per vial.

From research and development all the way to commercial distribution, we can deliver large quantities down to single patient samples. So no matter what the pharma industry produces, we can ensure the safety and efficacy of medicines for every phase of the pharmaceutical life cycle.

For more information, please visit www.envirotainer.com